GORE® Protein Capture Devices with Protein A
Designed to improve productivity in protein A affinity purification of monoclonal antibodies, GORE Protein Capture Devices provide high binding capacity at short residence time.
+1 800 294 4673
+1 410 506 1715
+49 89 4612 3456
+800 4612 3456
+1 800 294 4673
+1 410 506 1715
THE NEW 250 ML, 500 ML AND 1 L GORE PROTEIN CAPTURE DEVICES CAN IMPROVE PRODUCTIVITY IN CLINICAL APPLICATIONS
GORE Protein Capture Devices in 1.0 mL, 3.5 mL, 9 mL, 58 mL, 116 mL, 232 mL, 250 mL, 500 mL and 1L sizes.
Traditional affinity chromatography technology has not kept pace with increased titers and other upstream process improvements, leading to bottlenecks and lower productivity in downstream protein A purification. To shorten processing times, traditional resin-based protein A is often over-sized or underutilized – simply to keep up.*
*Reference: “Disrupting Downstream Process Bottlenecks.” Genetic Engineering, June 14, 2018.
Increase productivity: GORE Protein Capture Devices with Protein A utilize a unique membrane solution that provides a binding capacity advantage at high flow rates and improves the speed of purification versus traditional protein A resin technologies. Compare our Dynamic Binding Capacity (DBC) to that of agarose bead-based columns:
GORE Protein Capture Devices are approximately 6–10x faster than traditional (agarose bead-based) chromatography methods, which operate at typical residence times of 3–5 minutes (180–300 seconds).
Designed for affinity purification in early drug discovery screening, late stage optimization, process development, clinical and routine bioprocessing for
- monoclonal antibodies (mAbs)
- next-generation molecules that utilize the Fc region for Protein A binding
The columns are compatible with standard chromatography systems.
|PROA101||1.0 mL Device||Drug discovery|
|PROA102||3.5 mL Device||Drug discovery|
|PROA103||9.0 mL Device||Drug discovery, late stage optimization, process development, early GMP applications|
|PROA201||58 mL Device||Process development, clinical (GMP) applications|
|PROA202||116 mL Device||Clinical (GMP) applications|
|PROA203||232 mL Device||Clinical and Routine Manufacturing (GMP) applications|
|PROA301||250 mL Device||Clinical and Routine Manufacturing (GMP) applications|
|PROA302||500 mL Device||Clinical and Routine Manufacturing (GMP) applications|
|PROA303||1 L Device||Clinical and Routine Manufacturing (GMP) applications|
GORE Protein Capture Devices with immobilized Protein A* can improve throughput and yields in downstream purification by reducing overall process time through a combination of increased binding capacity and fast flow rates. These pre-packed columns use a unique membrane that offers high dynamic binding capacity at short residence time. Designed to increase the efficiency of protein A column purification processes, the Devices accommodate rapid cycle capability at low pressure drop, along with demonstrated ability to withstand multiple cleaning cycles. This increased productivity offers researchers the potential for a faster path to clinical trials.
|GORE Protein Capture Devices with Protein A (all sizes)|
|Dynamic binding capacity||≥ 30 mg/mL||≥ 40 mg/mL|
|Residence time||20 seconds||30 seconds|
|Number of cleaning cycles||0.2 N NaOH for 3 minutes up to 100 cycles||0.2 N NaOH for 3 minutes up to 100 cycles|
*recombinant Protein A
The GORE Protein Capture Device scales across sizes without compromising binding capacity or speed to quickly and effectively capture antibodies as shown in this overlay of a 1 mL, 9 mL and 58 mL bind-elute curve and dynamic binding capacity graph.
Want complete technical and product performance information, including detailed test parameters, additional yield data, purity profiles and operating conditions?
The GORE Protein Capture Devices with Protein A can streamline antibody purification processes because they incorporate a proprietary membrane composite.
Unlike traditional support matrices, the composite membrane bed maintains a linear relationship between pressure drop and a wide range of flow rates. Because this unique structure remains stable, the membrane bed is not vulnerable to collapse, channeling or alteration of the bed.
Performance under pressure
Pressure Drop for a 58 mL Device (PROA201)
Pressure drop consistency
Materials of construction
|Components||GORE PART NUMBER|
|Device housing components||Polypropylene||Polypropylene and Polyether ether ketone (PEEK) primarily*|
|Frit material(s)||Polypropylene||Polyether ether ketone (PEEK)
Polyvinylidene fluoride (PVDF)
|Membrane support matrix||Proprietary composite|
|Ligand||Recombinant Protein A|
|Connectors||10-32 threaded fittings (PROA101/PROA102)
10-32 coned thread port (PROA103)
|5/16-24 Flat-bottom fittings (PROA201)
1/2-20 flat-bottom threaded fittings (PROA301)
|3/4" Tri clamp
* For details:
GORE Protein Capture Devices are compatible with standard pre-packed column chromatography systems, and are available in sizes as listed in table below. Contact Gore for pricing and availability. These Devices for protein A purification are not available in all regions.
Part Number/Ordering Information
|PROA101||1.0 mL Device|
|PROA102||3.5 mL Device|
|PROA103||9.0 mL Device|
|PROA201||58 mL Device|
|PROA202||116 mL Device|
|PROA203||232 mL Device|
|PROA301||250 mL Device|
|PROA302||500 mL Device|
|PROA303||1 L Device|
See Validation Guides for performance specifications and evaluations.
Regulatory Compliance and Quality
GORE Protein Capture Devices are manufactured following the applicable material quality and regulatory requirements, including relevant Good Manufacturing Processes as defined in the Gore PharmBIO quality system which is certified to ISO 13485 and ISO 15378. For current applicable compliance statements and quality control information:
Application Note: Cleaning Protocols to Reduce Effects of Pressure Rise Over the Lifetime of a GORE® Protein Capture Devices
Technical Information, 471.19 KB
Data Sheet: GORE Protein Capture Device for Early Clinical Applications, 9.0mL (PROA103)
Data Sheets, 230.71 KB
GORE PHARMBIO INTRODUCES 250ML, 500ML AND 1L PROTEIN CAPTURE DEVICES WITH PROTEIN A TO DELIVER CONSISTENT SCALABILITY AND INCREASED PRODUCTIVITY ACROSS SIZES
Posted April 11, 2023
W. L. Gore & Associates, Inc. (“Gore”), a global materials science company, continues to build on its growing portfolio of protein capture devices with the introduction of its 250mL, 500mL and 1L GORE® Protein Capture Devices with Protein A. The offerings follow commer-cial availability of its 116mL and 232mL sizes introduced in mid 2022.
Join W. L. Gore & Associates for the Live + Virtual Bioprocessing Summit Europe
March 14, 2023 - March 16, 2023
Join W. L. Gore & Associates at BioProcessing Summit Europe, Europe’s Premier Conference to Optimize Your Bioprocesses
Visit GORE at BioProcess International in San Diego
February 27, 2023 - March 2, 2023
Join W. L. Gore & Associates for BioProcess International, the largest BioProcessing event for learning how to accelerate promising biologics, cell & gene therapies towards commercial success.
AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies
Posted December 12, 2022
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the global CDMO’s contract development and manufacturing services. By using GORE and AGC Biologics, biopharmaceutical companies can improve downstream purification processes, eliminate column bioburden issues, increase product material yields in the research and development (R&D) stages, and help lower costs for clinical manufacturing.
NOT INTENDED FOR USE in medical device or food contact applications or with radiation sterilization.
Follow GORE® Protein Capture Devices with Protein A